| Expression pattern: |
DN |
| Associated gene: |
MeCP2, Mobp, Igfbp3, Fxyd1, Prodh |
| Associated microRNA: |
- |
| Biological function: |
Promotes functional recovery after ischemic stroke, enhances neuronal plasticity, inhibits glial activation and peripheral immune cell infiltration, and improves motor recovery in rodent and nonhuman primate stroke models. |
| Molecular mechanism: |
circSCMH1 binds MeCP2 and releases repression of MeCP2 downstream target genes, including Mobp, Igfbp3, Fxyd1, and Prodh; EV-mediated delivery targets circSCMH1 to the brain. |
| Biological pathway or process: |
other pathway/process (promotes); immune regulation (inhibits); inflammation (inhibits); mRNA stability (other) |
| Detected method: |
Q
M
|
| Validation methods: |
Back-Splice Junction PCR / divergent primers PCR; RNase R Treatment; RT-qPCR; Microarray; Clinical Sample Validation; ISH (In Situ Hybridization); IF (Immunofluorescence); RIP (RNA Immunoprecipitation); RNA Pull-Down; Transfection; Flow Cytometry（Non-apoptosis/cycle）; In Vivo Animal Model; Western Blot; ELISA; ROC Analysis; Bioinformatics Analysis |
| Clinical significance: |
circSCMH1 level had diagnostic power for AIS and predicted stroke outcomes; lower baseline circSCMH1 levels were associated with poor outcomes. |
| Description: |
circSCMH1 is decreased in plasma from AIS patients and in mouse stroke models, and its level has diagnostic and outcome-predictive value. Therapeutic delivery of circSCMH1 via engineered RVG-EVs improves functional recovery after ischemic stroke in rodents and nonhuman primates by promoting neuronal plasticity and suppressing glial activation and peripheral immune cell infiltration. Mechanistically, circSCMH1 binds MeCP2 and releases repression of MeCP2 downstream target genes such as Mobp, Igfbp3, Fxyd1, and Prodh. |
| Confidence score: |
0.8508 |